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Interleukin‑26 activates 
macrophages and facilitates killing 
of Mycobacterium tuberculosis
Heike C. Hawerkamp 1, Lasse van Geelen 2, Jan Korte2, Jeremy Di Domizio 3, 
Marc Swidergall 4, Afaque A. Momin 5, Francisco J. Guzmán‑Vega5, Stefan T. Arold 5, 
Joachim Ernst4, Michel Gilliet 3, Rainer Kalscheuer2, Bernhard Homey1 & Stephan Meller1*
Tuberculosis‑causing Mycobacterium tuberculosis (Mtb) is transmitted via airborne droplets followed 
by a primary infection of macrophages and dendritic cells. During the activation of host defence 
mechanisms also neutrophils and T helper 1  (TH1) and  TH17 cells are recruited to the site of infection. 
The  TH17 cell‑derived interleukin (IL)‑17 in turn induces the cathelicidin LL37 which shows direct 
antimycobacterial effects. Here, we investigated the role of IL‑26, a  TH1‑ and  TH17‑associated cytokine 
that exhibits antimicrobial activity. We found that both IL‑26 mRNA and protein are strongly increased 
in tuberculous lymph nodes. Furthermore, IL‑26 is able to directly kill Mtb and decrease the infection 
rate in macrophages. Binding of IL‑26 to lipoarabinomannan might be one important mechanism 
in extracellular killing of Mtb. Macrophages and dendritic cells respond to IL‑26 with secretion of 
tumor necrosis factor (TNF)‑α and chemokines such as CCL20, CXCL2 and CXCL8. In dendritic cells 
but not in macrophages cytokine induction by IL‑26 is partly mediated via Toll like receptor (TLR) 2. 
Taken together, IL‑26 strengthens the defense against Mtb in two ways: firstly, directly due to its 
antimycobacterial properties and secondly indirectly by activating innate immune mechanisms.
Mycobacterium tuberculosis (Mtb)1–3 is the causing agent of tuberculosis in humans. Tuberculosis is among the 
top 10 causes of death worldwide, infecting 10.0 million people and causing 1.5 million deaths in  20184.
A complex interplay between host- and pathogen-specific factors determines the outcome of the  infection5. 
Tuberculosis is transmitted via airborne droplets containing Mtb which initially infects, and mainly resides intra-
cellularly in macrophages and also in dendritic cells (DCs)6. Mycobacteria enter both cell types via phagocytosis.
The host uses several lines of defense comprising components of the innate as well as the adaptive immune 
system. Upon infection by Mtb macrophages, DCs, neutrophils, and natural killer (NK) cells detect the pathogen 
via pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs), Nod-like receptors and C-type lectin 
 receptors7. During early infection, macrophages serve as a major site for Mtb  replication8. During granuloma 
formation in later stages Mtb may persist in  macrophages8.
Various endogenous agents such as granulysin, human beta-defensin 2 (hBD2)9,10, and LL37 are able to 
kill Mtb in vitro11–13. All of these agents attack Mtb extracellularly as well as inside macrophages. LL37 and 
hBD2 are secreted by granulocytes as well as epithelial cells and belong to the group of cationic antimicrobial 
peptides defined by their protein properties and their ability to kill  bacteria14. Antimicrobial peptides (AMP) 
protect epithelial surfaces and are part of the innate immune  system14. Most AMP are cationic peptides sharing 
the affinity for negatively charged molecules found in the cell envelope of many  germs15. Briefly, the binding 
of AMP to a negatively charged microbial compound thins the envelope, finally leading to a pore formation 
and microbial death by disrupting the cell  membrane14. Among other proteins and AMPs, LL37 released by 
neutrophils together with nucleic acids forms neutrophil extracellular traps (NETs). As part of the innate host 
response, NETs are released upon contact with  mycobacteria16. Macrophages are able to uptake these NETs 
containing LL37. Within lysosomal compartments, these AMP-nucleic acid complexes display antimicrobial 
activity against  mycobacteria17. Several subtypes of T cells play central role during Mtb infection: Similar to NK 
cells, cytolytic T lymphocytes and γδ T cells release granulysin and perforin that lyse infected macrophages and 
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inhibit mycobacterial  growth10,18,19.  TH1 cells are considered to be the main effector  CD4+ T cells during tuber-
culosis infection. Activated  TH1 cells secrete IFN-γ that induces antimycobacterial activity in  macrophages13,20,21. 
Recently, we demonstrated that interleukin-26 (IL-26), a cytokine mainly produced by  TH1 and  TH17  cells22, but 
also by innate cells such as NK  cells23 and  macrophages24, displays antimicrobial  activity22. Zhang et al.25, showed 
that IL-26 levels were much higher in tuberculous pleural effusion compared to the corresponding serum. They 
also demonstrated that IL-26 is induced in  TH1 and  TH17 cells upon stimulation with ESAT-6/CFP-10, a Mtb-
specific heterodimeric antigen complex25. Interestingly, circulating levels of IL-26 decrease after anti-tuberculosis 
 treatment26. It was intriguing to assess if IL-26 displays direct antimycobacterial activity.
Results
IL26 mRNA is significantly upregulated in both tuberculous lymph nodes and cutaneous sar‑
coidosis. A pathological hallmark of tuberculosis is the formation of granulomatous lesions in infected tis-
sues. Comparing lymph nodes (LN) with granulomas from tuberculosis patients to healthy controls by qPCR, 
we detected a significantly increased gene expression of IL26 in LN from patients suffering from tuberculosis 
compared to LN from healthy individuals (Fig. 1a). In addition, IFNG (Supplemental Fig. 1a) and IL22 gene 
expression (Fig. 1a) is also increased in tuberculosis LN, but the expression of IL17A was unaffected (Fig. 1a). In 
line with the gene expression results IL-26 protein was found to be increased in LN from tuberculosis patients 
(Fig. 1b upper left and upper middle panel) using immunohistochemistry. In healthy lymph nodes minimal 
staining for IL-26 was detected (Fig. 1b lower left and lower middle panel).
Another disease with granulomatous appearance similar to tuberculosis is sarcoidosis. Here, we focused on 
cutaneous sarcoidosis and also report a significant increase in IL26 gene expression whereas the gene expressions 
of IL22 and IL17A were not affected (Fig. 1c). Similarly to tuberculous LN, a significantly increased gene expres-
sion of IFNG was observed (Supplementary Fig. 1b). Beside the amended gene expression of IL-26, a strongly 
increased staining for IL-26 protein in the dermal layer of sarcoidosis skin sections was seen (Fig. 1d upper 
panel). In healthy skin there was only faint IL-26 staining (Fig. 1d lower panel), while strong IL-26 straining was 
found in psoriatic skin that served as a positive control (Supplementary Fig. 1c)27. Here, the staining appears to 
be mainly associated with infiltrating lymphocytes and proliferating lymphocytes.
Antimycobacterial activity of IL‑26 is supported by binding to lipoarabinomannan (LAM) and 
via reduced infection rate in macrophages. Since we have demonstrated previously that IL-26 is capa-
ble of killing some microbes  directly22, we were wondering if this also applies to mycobacteria. Performing a 
microbroth dilution assay, we found that IL-26 was indeed able to restrict growth of Mtb (Fig. 2a). IL-26 was 
similarly effective in inhibiting growth of Mtb as LL37, resulting in a minimal inhibitory concentration (MIC50) 
of 6 µM compared to 4 µM for LL37 (Fig. 2a). The antimycobacterial effect of IL-26 is completely inhibited in the 
presence of a blocking anti-IL-26 antibody (Fig. 2a). As expected, the antimycobacterial agent rifampicin showed 
its strong efficiency also in minimal concentrations (Fig. 2a). To evaluate morphologic changes in mycobacteria 
in presence of IL-26, we incubated Mtb with 12.5 µM IL-26 or LL37 (positive control) and subsequently prepared 
the samples for scanning electron microscopy (SEM). The SEM revealed that IL-26 induced “bleb” formation 
on mycobacteria after 24 h indicative of cell wall damage (Fig. 2b). As most AMPs target components of the 
mycobacterial cell envelope, we investigated if the major mycobacterial cell-wall glycolipid lipoarabinomannan 
(LAM) might be targeted by IL-26. Since LAM is known to interact with cationic  molecules28 we investigated 
if LAM binds to the cationic IL-26 using microscale thermophoresis and detected a strong affinity of IL-26 to 
mannosylated (Man) LAM from Mtb H37Rv (Fig. 2c). The calculated dissociation constants were as low as 1 nM 
for IL-26 to LAM from Mtb H37Rv and also to LAM from M. smegmatis (Supplementary Fig. 2a). Moreover, 
we used computational docking to investigate the molecular basis for the observed interaction between LAM 
and IL-26 (see “Materials and methods” for details). We performed docking based on the predicted IL-26 struc-
ture and on LAM fragments obtained from experimental structure of LAM-protein complexes, namely the oli-
goarabinofuranosyl tetrasaccharide (complexed to fab; PDB id 3HNT) and Alpha-d-mannose beta-d-mannose 
N-acetyl-d-glucosamine saccharide (complexed to Mycobacterial lipoglycan; PDB id 2GAZ). Without impos-
ing a specific docking site on IL-26, in all high-ranked docking poses both LAM fragments bound to the same 
surface groove on IL-26 (Supplementary Fig. 2b). The residues surrounding the putative binding site consist of 
Arg65, Glu155, Asp157, Ser161 forming hydrogen bonds with the ligand, whereas Phe75 and Trp162 involved 
in hydrophobic interactions (Supplementary Fig. 2c,d). ConSurf  analysis29 revealed that the binding site residues 
have intermediate to high conservation (falling in score 5–9 on a scale of 0–9).
The putative LAM binding site is in turn adjacent to a strongly electro-positive region found in the predicted 
model. The existence of this region was also suggested by Meller et al.22. An amphipathic structure, the clustering 
of cationic charges and the formation of multimers are hallmarks of antimicrobial  peptides14. These clustered 
Figure 1.  IL-26 is over-expressed in tuberculous lymph nodes and cutaneous sarcoidosis. (a, c) qPCR analysis 
of gene expression of IL26, IL22 and IL17A in tuberculous LN (a, n = 12) compared to healthy control LN (n = 9) 
in RNA from formalin-fixed paraffin-embedded (FFPE) lymph nodes and sarcoidosis skin punch biopsies (c, 
n = 4–6) compared to healthy skin controls (n = 10). qPCR-values are depicted as relative units compared to 
18S RNA expression. Data are presented as single values and mean ± SEM. Mann–Whitney U test was used 
to evaluate significant differences (*p < 0.05, **p < 0.01 and ***p < 0.001). (b, d) immunohistochemistry with 
anti-IL-26 and isotype control on FFPE lymph node (LN) sections (10 µm) from one representative tuberculosis 
patient or healthy control and sections (4 µm) from skin punch biopsies from one representative sarcoidosis 
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charges have also been shown to form complexes with extracellular  DNA30. Furthermore, Meller et al.22 found 
IL-26 to be capable of disrupting bacterial membranes by pore formation, and also to bind extracellular DNA 
from both bacterial and human dying cells.
Mtb primarily invades phagocytic cells such as macrophages or dendritic cells. Within these cells, Mtb may 
persist and proliferate in modified, host-derived  phagosomes6,31. A central step in antimycobacterial defense is 
the phagosome-lysosome fusion leading to the formation of phagolysosomes and subsequent killing of  Mtb31. 
Therefore, we investigated if IL-26 is affecting the intracellular killing of Mtb in macrophages using a fluorescent 
Figure 2.  IL-26 displays extracellular antimycobacterial activity against Mtb H37Rv and improves intracellular 
killing of Mtb H37Rv pBEN::mCherry in THP1 macrophages. Growth of MtbH37Rv (a) treated with increasing 
concentrations of IL-26 or LL37 was analyzed using the resazurin assay (n = 3–6). (b) Scanning electron 
microscopy of untreated Mtb (left picture), IL-26-treated Mtb (middle picture) and LL37-treated Mtb (right 
picture). (c) Binding of IL-26 to mycobacterial ManLAM was investigated using microscale thermophoresis 
(MST). The percentages of bound fractions of LAM from Mtb H37Rv to different IL-26, IL-22 and LL37 
concentrations are displayed graphically. (d) CFUs from infected THP1 macrophages after treatment with IL-26 
(n = 3). Data are presented as mean ± SEM. Statistical analysis was done using Wilcoxon matched pairs signed 
rank test (* equals p < 0.05, ** equals p < 0.01).
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Mtb reporter strain. THP-1 macrophages were infected for 3 h before the addition of IL-26 or LL37 as a control. 
After 5 days the amount of intracellular mycobacteria was investigated by analysis of colony forming units (CFU). 
We found a highly significant decrease in presence of rifampicin, but also IL-26 significantly reduced the number 
of CFUs (Fig. 2d). This implies that IL-26 has intracellular antimycobacterial properties. Preincubation of IL-26 
with the blocking anti-IL-26 antibody diminished the intracellular antimycobacterial effect of IL-26 (Fig. 2d).
IL‑26 induces chemokines as well as cytokines and signals via TLR2. We then investigated if IL-26 
affects (uninfected) macrophages. Having shown that IL-26 is highly expressed on both gene and protein levels 
in tuberculosis LN with granulomas—in the latent inactive disease state—packed with different immune cells, 
we wondered if IL-26 would play a role in cell recruitment via chemotaxis. Treating both THP1 and primary 
macrophages with IL-26, we found an enhanced gene expression of CCL20, CXCL8 and CXCL2 (Fig. 3). Com-
paring this IL-26-induced chemokine induction in THP1 macrophages to treatment with LL37, we found that 
LL37 induces CCL20 even stronger than IL-26. For CXCL2, LL37 leads to a slight increase, while CXCL8 is not 
induced by the presence of LL37 (Fig. 3a).
IL-26 mediates its biological effects through a receptor dimer composed of the IL-20 receptor 1 (IL-20R1) 
and IL-10 receptor  232,33 or in conjunction with nucleic acids via  TLR922. However, macrophages as well as 
monocyte-derived dendritic cells (moDCs) do not express IL-20R2 and no IL-26-DNA complexes were used 
in the experiment mentioned above. Seeing the antimicrobial and antimycobacterial effects of IL-26 and thus a 
link between adaptive and innate immune responses, we wondered if IL-26 might be able to transduce its signals 
via TLRs. Indeed, TLR2 has been shown to be of importance in the signalling of the antimicrobial human beta-
defensin (hBD)-334. Since TLR2, an anionic membrane receptor expressed by  leukocytes35 that binds exogenous 
as well as endogenous  agents36 that may internalized leading to cell  activation37 and since CXCL2 expression 
upon Mtb infection involves TLR2  signaling38, we were wondering if IL-26 uses TLR2 to mediate chemokines 
and cytokine expression in these cells.
In fact, gain-of-function experiments using a TLR2 reporter gene assay confirmed that IL-26 induces NF-κB 
in TLR2-transfected HEK293 cells (Fig. 4a). The presence of an anti-TLR2-antibody completely blocked the 
effects of IL-26. Additionally, stimulating the TLR2-transfected HEK293 cells with LL37 revealed no response 
(Fig. 4a). When stimulating the parental control cell line to the TLR2-transfected HEK cells, the HEK Null1 
cells, with IL-26 or LL37, no SEAP secretion is observed (Fig. 4b). The HEK Null1 cells also did not respond 
to LPS nor LTA, but strongly to 100 ng/mL TNF-α. Next, we compared TLR2 knockdown THP1 macrophages 
Figure 3.  IL-26 induces chemokines in THP1 and primary macrophages. Gene expression of CCL20, CXCL2 
and CXCL8 detected via qPCR in PMA-differentiated THP-1 macrophages (a) or primary macrophages (b) 
stimulated with IL-26 and LL37 for 24 h (n = 6). qPCR-values are shown as relative units compared to 18S RNA 
expression. Data are presented as mean + SEM. Statistical analysis was done using Wilcoxon matched pairs 
signed rank test (* equals p < 0.05).
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to the standard THP1 macrophages in terms of their TNF-α and IL-6 secretion as response to IL-26 treatment 
(Fig. 4c). Successful TLR2 knockdown using siRNA in THP1 macrophages was confirmed via flow cytometry 
(Supplementary Fig. 3a,b), qPCR (Supplementary Fig. 3c) and confocal microscopy (Supplementary Fig. 3d). 
TLR2 knockdown did not interfere with LPS-induced TNF-α and IL-6 secretion, but treatment with LTA did not 
lead to TNF-α and IL-6 secretion (Fig. 4c). IL-26 significantly increased TNF-α secretion but had no effect on 
IL-6 in normal THP1 macrophages. TLR2 knockdown slightly reduced TNF-α secretion after IL-26 treatment 
as compared to TLR2-competent macrophages, while IL-6 secretion seemed to be enhanced in IL-26-treated 
TLR2 knockdown macrophages compared to control macrophages (Fig. 4c). Regarding chemokine expressions, 
there seems to be an impaired induction of CXCL1 and CXCL8 in TLR2 knockdown macrophages as compared 
to controls (Supplementary Fig. 3e).
To get closer to the nature of tuberculosis with involvement of different cell types including antigen-presenting 
cells such as DCs, we simulated a TLR2 inhibition using a blocking anti-TLR2-antibody. Here, we compared 
anti-TLR2 antibody treatment in THP1 macrophages, primary macrophages and finally monocyte derived DCs 
(Fig. 4d). The presence of IL-26 led to a significantly increased TNF-α secretion in all three cell types with the 
strongest effect in moDCs. IL-26 dependent induction of TNF-α secretion was reduced by adding an inhibitory 
anti-TLR2 antibody in moDCs (Fig. 4d). This inhibition in moDCs is not seen when IL-26 is co-incubated with 
an anti-IgA2 control antibody (Fig. 4d). In contrast, an inhibitory anti-TLR2 antibody did not affect the TNF-α in 
THP1 and primary macrophages (Fig. 4d). We wondered if this different reaction to TLR2 blockade or knockout 
might be due to variations in TLR2 gene expressions in these cell types. Indeed, baseline TLR2 gene expression 
in untreated THP1 and primary macrophages as well as moDCs is roughly identical (Fig. 4e). Interestingly, 
IL-26 significantly induced the gene expression of TLR2 in moDCs but not in THP1 nor primary macrophages 
(Fig. 4e). Taken together, IL-26 signalling via TLR2 seems to be a cell dependent mechanism. A strongly increased 
TLR2 gene expression was found in lymph node of patients suffering from tuberculosis compared to healthy 
subjects (Fig. 4f). In skin biopsies from sarcoidosis patients a strong trend (p = 0.0539) towards increased TLR2 
expression was observed (Fig. 4g).
We report that IL-26 is able to kill mycobacteria directly (Fig. 5). This killing might be supported through 
binding to LAM on mycobacterial surface. Furthermore, we showed that the presence of IL-26 improves the 
intracellular killing of Mtb within macrophages. The increased expression of CCL20, CXCL2, CXCL8 and TNF-α 
of uninfected macrophages in response to IL-26 may lead to the attraction of  TH17 cells and neutrophils to 
inflammation sites (Fig. 5).
Discussion
We report here that both IL-26 gene and protein expression are significantly increased in tuberculosis and 
sarcoidosis. The detection of IL-26 in granulomatous lesions of tuberculosis is surprising since LL37, an anti-
microbial peptide with great impact on tuberculosis  infection11,12, was reported to be mostly absent in these 
chronic lesions of  tuberculosis39. Among others, LL37 expression is induced by the  TH17 cytokine IL-1740, which 
was almost undetectable in our cohort.  TH17 cells also release IL-26 and IL-22. Since IL-26 and IL-22 can also 
be secreted by other tuberculosis-associated lymphocyte subsets than  TH17 such as  TH1 cells or by NK  cells41,42, 
our findings point to  TH1 cells or NK cells as cellular source of IL-26 in granulomatous lesions of tuberculosis.
IL-26 is capable of inhibiting Mtb and creating blebs on the mycobacterial cell surface. Antimicrobial activity 
against mycobacteria has been shown recently where IL-26 had killing effects on M. leprae and the attenuated 
M. tuberculosis strain  H37Ra43. Comparing the data from the attenuated strain to our data with the virulent Mtb 
H37Rv, it seems as if Mtb H37Rv is more resistant to IL-2643. Treating other microbes with IL-26 has revealed this 
antimicrobial phenomenon previously as  well22. Similar surface lesions on Mtb are caused by granulysin, a protein 
released by cytolytic T cells during antimycobacterial  responses10. The cell envelope of mycobacteria contains 
several pathogen-associated molecular patterns (PAMPs)44. These PAMPs are recognized by macrophages and 
DCs through PRRs such as  TLRs44. The PAMP LAM is a key component of the mycobacterial cell surface and 
an important virulence factor that is thought to bind  TLR244,45. Since LAM interacts with cationic  molecules28 
we tested its binding to cationic IL-26 and found a strong affinity. Our computational modelling analysis sug-
gests that IL-26 possesses a region that is capable of binding to oligosaccharides. Given the large size of LAM, 
a multimer of several IL-26 molecules might bind collaboratively to one LAM molecule, explaining the high 
affinity. Considering LL37, it binds with similar affinity as IL-26 to LAM from M. smegmatis but it basically does 
not bind to LAM from Mtb. LAM from Mtb is decorated with terminal mannose residues resulting in Man-
LAM whereas LAM from M. smegmatis lacks this mannose cap. Instead, M. smegmatis LAM is terminated by 
phosphoinositol, yielding PI-LAM46. The additional negative charge in PI-LAM vs. Man-LAM might explain 
Figure 4.  IL-26 exerts effects on moDCs via TLR2. (a) Secreted embryonic alkaline phosphatase (SEAP) 
reporter assay was used to determine if IL-26 is able to signal via TLR2 (n = 4). (b) HEK Null1 cells are the 
parental cell line and are used as controls (n = 3). Statistical analysis was done using Mann Whitney U test (* 
equals p < 0.05). (c) TNF-α and IL-6 secretion in THP1 macrophages treated with siTLR2 or control siRNA 
(siCTL) (n = 2). (d) TNF-α secretion by THP1 macrophages, primary macrophages and moDCs treated with 
IL-26 or pretreated with anti-TLR2-antibody for 45 min before the addition of IL-26 for another 24 h and 
measured via ELISA (n = 6). (e) TLR2 gene expression after IL-26 stimulation in THP1 macrophages, primary 
macrophages and DCs (n = 5), or comparing tuberculosis (f) or sarcoidosis (g) to their respective healthy 
control. Data are presented as mean + SEM or a single dot is representing one independent sample. Statistical 
analysis was done using Wilcoxon matched pairs signed rank test (* equals p < 0.05) or Mann–Whitney U test 
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the differential binding of the cationic peptide LL37. Taken together, LAM represents one potential target of the 
mycobacterial cell wall that—among others—enables IL-26 to attack Mtb extracellularly.
Tuberculosis is characterized by a primary infection of macrophages. We found that the presence of IL-26 
improves macrophage survival by decreasing the infection rate of Mtb. This result is in line with a study from 
Dang et al. showing that IL-26 has similar effects in macrophages infected with M. leprae, Mtb H37Ra or S. 
aureus43. Furthermore, uninfected macrophages respond to IL-26 with increased TNF-α secretion and increased 
expression of the chemokines CCL20, CXCL2 and CXCL8. Importantly, TNF-α is a key molecule in tuberculosis 
defence and an important therapeutical target in sarcoidosis released by monocytes after activation via  TLR247. 
TNF-α induces autophagy and is crucial for the formation of well-organized granulomas. Inhibition of this 
cytokine goes along with deterioration or reactivation of tuberculosis, absence of TNF-α is associated with fatal 
tuberculosis  progression48. Furthermore, the expression of CCL20, CXCL8 and CXCL2 has been implicated in 
the pathogenesis of tuberculosis. CCL20 is highly upregulated in Mtb-infected macrophages. This may help to 
recruit more DCs to the site of  inflammation49. However, the exact role of CCL20 in tuberculosis remains to be 
clarified. CXCL8 was reported to bind to the Mtb cell surface to increase the potency of leukocytes to phagocytose 
the germ. The same group suggested that CXCL8, well known as neutrophil attracting chemokine, may serve as 
a major chemokine for recruiting  CD3+,  CD4+, and  CD8+ T  cells50. Recent studies indicate that CXCL2 mediates 
the induction of beta-defensins as well as it is involved Mtb-dependent IL-1β  production38,51.
As IL-26 acts on the interface between innate and adaptive immunity, we hypothesized that a TLR might act as 
its receptor on immune cells such as macrophages or DCs. Knowing that TLR2 signaling is involved in CXCL2 
 expression38 and additionally hBD3 signaling on antigen-presenting cells depends on  TLR234, we report that 
TLR2 serves as a putative receptor for IL-26 in a cell type dependent manner. Previous studies have demonstrated 
that activation of TLR2 leads to the induction of antimicrobial responses including the expression of LL37 and 
intracellular killing of Mtb via the upregulation of vitamin D receptor and vitamin D-1-hydroxylase  genes12. An 
induction of TLR2 expression in presence of a ligand has been reported for  LPS52. To date, it was known that the 
activation of TLR2 is mediated by bacterial  components52,53. Interestingly, the antimycobacterial T cell protein 
Figure 5.  Proposed summarizing model.  TH1 cell-derived IL-26 is increased expressed in lymph node in 
tuberculosis patients. IL-26 shows direct antimycobacterial activity. This activity which is possible mediated via 
binding of IL-26 to mycobacterial surface molecule LAM. Besides direct activity against mycobacteria, IL-26 
also improves intracellular killing of mycobacteria in THP1 macrophages. Furthermore, IL-26 induces cytokines 
such as TNF-α and chemokines such as CCL20, CXCL8 and CXCL2 in macrophages. CCL20 leads then to the 
further recruitment of T cells to the side of infection and CXCL8 as well as CXCL2 are attracting neutrophils.
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granulysin exerts its effects on antigen-presenting cells via  TLR454. IL-26 does not use TLR4 signalling (data 
not shown). Here, we demonstrated that a T cell-derived cytokine is able to activate TLR2 and this way it may 
enhance innate immune responses.
In the context of sarcoidosis these results provide new puzzle pieces of the largely unknown pathogenesis of 
this disease suggesting a role of IL-26 in the activation of moDCs via TLR2 followed by the secretion of TNF-α, 
an important pathological player and therapeutical target in sarcoidosis.
To conclude, we report that IL-26 is able to kill mycobacteria directly. This killing might be mediated through 
binding to LAM on mycobacterial surface. Furthermore, we showed that the presence of IL-26 improves the 
intracellular killing of Mtb within macrophages. Macrophages (uninfected) also respond to IL-26 with increased 
expression of TNF-α as well as CCL20, CXCL2 and CXCL8. These may lead to the attraction of  TH1  cells55 
and neutrophils to inflammation sites. CXCL8 has additionally been shown to enhance Mtb killing within 
 macrophages56. The increased gene expression of CXCL8 might therefore provide a mechanism how IL-26 
enhances intracellular Mtb killing. It was further demonstrated that secreted CXCL8 binds to Mtb and increases 
phagocytosis of the  mycobacteria50.
Material and methods
Study approval. Formalin-fixed paraffin-embedded (FFPE) sections (10  µm) from lymph nodes from 
healthy subjects (n = 9, mean age: 51.6 years) and patients with tuberculosis (n = 12, mean age: 29.8 years) were 
provided by the Institute of Pathology, University Hospital Düsseldorf. Skin punch biopsies (sections: 4 µm) 
from sarcoidosis (n = 4–5, mean age: 64 years) and healthy skin (n = 10, mean age: 78 years) were taken after 
informed consent. Buffy coats from healthy donors were obtained from the Institute of Hemostasis and Transfu-
sion Medicine, University Hospital Düsseldorf. The study was performed according to the Declaration of Hel-
sinki and approved by the Ethics Committee, Medical Faculty of the Heinrich-Heine-University Düsseldorf (no: 
4028).
Immunohistochemistry. FFPE sections were incubated at 60 °C overnight and subsequently washed in a 
decreasing ethanol series. The sections were incubated for 20 min with demasking solution (pH 9; Dako Target 
Retrieval), washed in PBS and subsequently incubated in  H2O2 for 10 min. After washing, the sections were 
incubated with 10% human serum and streptavidin (Vector Laboratories, USA) for 30 min at room temperature 
(RT). The primary antibodies, anti-IL-26 (Clone: 197505 unconjugated, R&D Systems, USA) and mouse IgG2b 
isotype (BD Biosciences, USA), were diluted in 1% human serum/PBS and biotin (Vector Laboratories, USA), 
adjusted to 2 µg/mL and incubated overnight at 4  °C. After washing, the sections were incubated with 10% 
horse serum for 15 min at RT. Thereafter the secondary antibody (biotinylated anti-mouse IgG; VectaStain) was 
applied for 30 min at RT. The sections were then incubated with streptavidin horseradish peroxidase (HRP, Dako 
Agilent Technologies, USA) for 45 min at RT followed by incubation with the AEC 2-Components Kit (DCS 
Chromokine, Germany) at RT and counterstaining with hematoxylin.
RNA isolation. RNA Isolation from skin biopsies was performed using Trizol separation, followed by the 
RNeasy Mini Kit (Qiagen, Venlo, Netherlands). RNA from cultured cells was isolated using the RNeasy Mini Kit. 
The RNeasy FFPE Kit (Qiagen) was used for FFPE sections.
Reverse transcriptase PCR. Four µg of RNA were added to 1.5 µL first strand buffer (Invitrogen), 1 µL 
 RNasin® Plus (Promega), 1 µL DNase I recombinant (Roche) and 2.5 µL  H2O. After the first incubation (20 min 
at 37 °C, 10 min at 70 °C), 1 µL oligo dT (Invitrogen), 0.4 µL random primer (Promega) and 2.6 µL  H2O were 
added and incubated for 10 min at 70 °C. Finally, 4.5 µL first strand buffer, 1.5 µL dNTP Mix (Bioline), 1 µL DTT 
(Invitrogen), 0.5 µL  RNasin® Plus, 1 µL  SuperScript® II Reverse Transcriptase (Invitrogen) and 1.5 µL  H2O were 
added to each sample. The samples were finally incubated for 50 min at 42 °C and then 10 min at 70 °C.
Quantitative (q)‑PCR. qPCR analysis was performed on a QuantStudio 6 Flex (Applied Biosystems). 
Briefly, the primer mix for the ribosomal 18 S control gene contained 12.5 µL TaqMan Master Mix (Applied 
Biosystems), 0.15 µL Ribosomal Probe (life technologies), 0.15 µL Forward Primer (life technologies), 0.15 µL 
Reverse Primer (life technologies) and 2.05 µL  H2O per sample. Ten µL of cDNA (25 ng) were analyzed. For 
 TaqMan® Assays (Applied Biosystems; IL17A (Hs00174383_m1), IL22 (Hs00220944_m1), IL26 (Hs00218189_
m1), CCL20 (Hs00171125_m1), CXCL2 (Hs00601975_m1) and CXCL8 (Hs00174103_m1)), 10  µL TaqMan 
Master Mix and 1 µL primer mix was added. For TLR2 primers (forward: cgttctctcaggtgactgctc, reverse: cctttg-
gatcctgcttgc), 12.5 µL SYBR Green Master Mix and 2.5 µL of a 2 µM primer mix were used.
Mycobacteria. Mycobacterium tuberculosis H37Rv (Mtb), (Albert Einstein College of Medicine, Bronx, 
USA) and M. bovis Bacille de Calmette et Guérin (BCG) (Institute Pasteur) were cultured in Difco™ Middle-
brook 7H9 Broth (BD, Franklin Lakes, US) supplemented with 10% ADS (5%, w/v bovine serum albumin frac-
tion V; 2%, w/v glucose; 0.85%, w/v sodium chloride), 0.5% (v/v) glycerol, and 0.05% (v/v) tyloxapol at 37 °C.
Microbroth dilution assay. Mtb and M. bovis BCG were diluted to a final concentration of 1 × 106 CFU/
mL in RPMI 1640 (incl.  NaHCO3 and l-Glutamine; Gibco) diluted 1:4 in distilled water. Now, 50 µL of diluted 
RPMI medium was transferred into all wells of the polypropylene 96-well-plate except the first column. In each 
well of the first column, the reagents to test [e.g. IL-26 (R&D Systems), LL37 (InvivoGen, USA), rifampicin 
(Sigma-Aldrich, Munich, Germany)] as well as controls were diluted. Controls included diluted RPMI 1640 
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without any added bacteria or bacteria in diluted RPMI 1640 as growth controls. Furthermore, to account for 
possible effects of the solvents/diluents, matching volumes of PBS (for IL-26, anti-IL-26 and LL37) and DMSO 
(for rifampicin) were added as controls as well. Thereafter, a twofold serial dilution was performed. For experi-
ments involving the blocking anti-IL26-antibody22, five dilutions of IL-26 (starting with 25 µM) were prepared 
in Eppendorf tubes and an equal amount of 10 µg/mL anti-IL-26 was added to each tube. This mixture was then 
incubated for 1 h at room temperature before transfer into the 96-well-plate. The mycobacteria were added in a 
volume of 50 µL. The 96-well-plate was incubated for 5 days at 37 °C, before an aliquot was obtained to deter-
mine colony forming units (CFU). Subsequently, 10 µL resazurin (Sigma-Aldrich) was added to 96-well-plate 
and measured after overnight incubation at RT using a plate reader (Ex/Em: 540/590 nm; TECAN  Infinite® 200; 
Männedorf, Switzerland).
Scanning electron microscopy. Mycobacteria (5 × 105 CFU/mL in diluted RPMI medium) were trans-
ferred into a 24-well-plate containing poly-l-lysine-coated round cover glasses. After addition of IL-26 or LL37, 
the mycobacteria were incubated for 24 h. The mycobacteria were fixed with 2.5% glutaraldehyde and 4% para-
formaldehyde (PFA). After refrigerated overnight incubation, the cover glasses were first washed with PBS fol-
lowed by a serial dehydration starting with 50% ethanol (EtOH) and increasing to pure EtOH. Thereafter the 
cover glasses were washed twice with 100% acetone. The dehydrated samples were then subjected to critical point 
drying (CPD). The dried cover glasses were sputtered with gold using a Manual Sputter Coater (Agar Scientific, 
Essex, UK). Scanning electron microscopy (SEM) was performed using a Leo 1430 VP (Zeiss, Jena, Germany).
Microscale thermophoresis. Purified lipoarabinomannan (LAM) from Mtb H37Rv and Mycobacterium 
smegmatis were obtained through BEI Resources, NIAID, NIH, USA. LAMs were labeled with the Alexa Fluor 
 488® Microscale Protein Labeling Kit (life technologies). A constant amount of Alexa488-labeled LAM (200 nM) 
was incubated for 15 min at 37 °C with serially diluted concentrations of IL-26, LL37 or IL-22 (R&D Systems) 
in microscale thermophoresis (MST) binding buffer (50 mM Tris and 0.05% Tween 20). Ten μL of the samles 
were loaded into standard Monolith NT Capillaries and analyzed on a NanoTemper Monolith NT.115 apparatus.
Computational modeling. The three-dimensional Interleukin-26 (IL-26) structure was modeled using 
the I-Tasser57 protein structure prediction server. The model was built for human IL-26 residues 22–171 (the 
first 21 residues are predicted to be a signal peptide; Uniprot entry Q9NPH9), based on different threading 
templates, including structures of IL-10, IL-19, IL-22 and IL-24 which have a sequence identity to IL-26 of 
23–28%. The best I-Tasser model for IL-2622–171 achieved a C-score of − 0.17 [the C-score ranges from − 5 (poor) 
to + 2 (excellent)], and a TM-score of 0.69 ± 0.12 (a TM-score of > 0.5 indicates a model of correct topology). 
The IL-26 model was used for molecular docking with a linear, terminal oligoarabinofuranosyl tetrasaccharide 
from lipoarabinomannan (LAM) obtained from its experimental structure with fab (PDB id 3HNT) and alpha-
d-mannose beta-d-mannose N-acetyl-d-glucosamine saccharide from its experimental structure with Myco-
bacterial lipoglycan (PDB id 2GAZ).
Flexible docking was performed using AutoDock 4.2 with specific coordinate file types for both protein and 
ligand, termed PDBQT files. The files were prepared using the AutoDock Tools 4.2 user  interface58,59. Water 
molecules were removed, polar hydrogens were added, and the structures were saved as PDBQT. The flexible 
ligand was prepared by assigning the atom types, analyzing hydrogen bond acceptors and donors with the 
aromatic and aliphatic carbon atoms. The root was defined for the torsion tree from which the rotatable bonds 
emanate and define the flexibility of the ligand. Finally, the rotatable bonds and torsion angles were assigned and 
the files were saved as  PDBQT60. The grid parameters were set in accordance to the binding  pocket61. Docking 
was performed using Lamarckian genetic algorithm (LGA) with population size of 150 individuals, 2.5 million 
energy evaluations, maximum of 27,000 generations, number of top individuals to automatically survive to next 
generation of 1, mutation rate of 0.02, crossover rate of 0.8, 10 docking runs, and random initial positions and 
conformations. The probability of performing local search on an individual in the population was set to 0.06 to 
get optimal  results62,63. The files were further analyzed using the PyMOL program (pymol.org).
THP‑1 macrophages. THP-1 monocytes (Deutsche Sammlung von Mikroorganismen und Zellkulturen 
GMBH) were cultured in RPMI 1640 medium (Gibco) supplemented with 10% FCS (without antibiotics). The 
cells (1 × 106 cells/mL) were used at 100 µL per well in a 96-well-plate. Adherent macrophages were generated by 
the addition of 50 nM phorbol 12-myristate 13-acetate (PMA, Sigma) overnight.
Intracellular killing assay with THP‑1 macrophages. THP-1 macrophages were washed twice with 
PBS and then rested for 3 h in RPMI medium. The cells were then infected with a Mycobacterium tuberculosis 
H37Rv reporter strain [Mtb pBEN::mCherry (Hsp60)], that expresses mCherry under control of a promotor of 
heat shock protein 60 (Hsp60). The THP-1 macrophages were infected with 3 × 105 mycobacteria (MOI = 3) in 
a final volume of 20 µL for 3 h. After 2 h of incubation, 10 µg/mL anti-hTLR2-antibody or anti-IgA2 control 
antibody (Both: InvivoGen) were added to the respective wells for the remaining 1 h incubation time. After 
another washing step, fresh medium including gentamycin (5 µg/mL, Sigma-Aldrich) was added to all wells. At 
this point the reagents such as IL-26 (final: 2 µM), LL37 (final: 10 µM), rifampicin (final: 10 µM) and controls 
were added. As untreated control served uninfected THP1 macrophages in RPMI, and as treated control served 
infected THP1 macrophages in RPMI. DMSO as solvent of rifampicin and PBS (for IL-26 and LL37) were used 
to exclude effects due solvents or diluents. The THP-1 macrophages were incubated at 37 °C for 5 days, before 
CFU plating was performed. In order to determine CFUs, THP1 macrophages were lysed using 0.05% SDS and 
serial dilutions were spread on agar plates.
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Stimulation of uninfected THP‑1 macrophages. Uninfected THP-1 macrophages (1 × 106 cells/mL) 
were cultured in RPMI 1640 medium (control) or stimulated with LPS (100  ng/mL, Sigma-Aldrich), LL37 
(10 µM) and IL-26 (2 µM) for 24 h at 37 °C. The supernatant was for ELISA and the cell pellets for gene expres-
sion analysis.
Secreted embryonic alkaline phosphatase (SEAP) reporter assay. HEK-Blue™ hTLR2 cells (Invi-
voGen) are human embryonic kidney cells (HEK293 cells) specially engineered to co-express human TLR2 and 
secreted embryonic alkaline phosphatase (SEAP). Furthermore, a CD14 co-receptor gene was introduced into 
these cells to enhance TLR2 response. The SEAP reporter gene is under the control of the NF-κB/AP-1 promoter. 
In those HEK-Blue™ hTLR2 cells stimulation with a TLR2 ligand will lead to SEAP secretion. The secreted SEAP 
can then be detected in real time using HEKBlue™ Detection, a specific cell culture medium. This medium con-
tains a substrate that upon hydrolysis by SEAP changes colour from pink to purple/blue. The control cells are 
the HEK-Blue™ Null1 cells (InvivoGen), which are the parental cell line and exhibit an endogenous expression of 
TLR3, TLR5 and NOD1, but are deficient for all other TLRs. The SEAP reporter assay for both cell lines was per-
formed according to manufacturer’s instructions. Briefly, 20 µL of each reagent or control were added per well in 
a flat-bottom 96-well-plate. In different experiments IL-26 (2 µM) or IL-26 (2 µM) in combination with 10 µg/
mL anti-hTLR2 (InvivoGen) have been used. Anti-hTLR2-antibody was added 45 min prior to addition of IL-26. 
As positive controls LTA (100 ng/mL; InvivoGen) was used in HEK-Blue™ hTLR2 cells, while TNFα (100 ng/mL; 
R&D Systems) was used in HEK-Blue™ Null1 cells. HEK-Blue™ hTLR2 cells were adjusted to a concentration of 
50,000 cells per well in HEKBlue™ Detection medium and incubated for 24 h. SEAP secretion as indicated by a 
change of cell culture medium colour from pink to purple or blue was measured at 620 nm.
Generation of TLR2 knockdown THP‑1 cells. THP-1 cells (ECACC, 88081201) were cultured in RPMI 
(incl. 2 mM Glutamine and 10% FBS) and were differentiated into macrophages by adding 150 nM PMA for 
24 h followed by a 4-day culture. THP-1 macrophages were washed and cultured in antibiotic-free medium 
24 h before siRNA transfection according to the manufacturer’s protocol (Santa Cruz Biotechnology). Basically, 
2 × 105 macrophages in a 6-well plate were washed with siRNA Transfection Medium and 1 mL of Transfection 
Medium containing 80 pmols of control siRNA (siCTL) or siRNA against human TLR2 (siTLR2) and 8 μL of 
Transfection Reagent was added to the cells. The cells were incubated for 6 h at 37 °C before 1 mL of culture 
medium was added. Forty-eight hours later, cells were assessed for TLR2 expression by flow cytometry.
Flow cytometry. Cells (5 × 105 cells) were washed and re-suspended in 100 μL of PBS (incl. 2% FBS and 
2 mM EDTA) containing 20 μL of FcR Blocking Reagent (Miltenyi) for 10 min at 4 °C. Cells were then stained 
with anti-human CD33-FITC (1/200, eBioscience, HIM3-4) and anti-human TLR2-PE (1/50, BioLegend, clone 
QA16A01) antibodies for 20 min at 4 °C. Cells were then washed twice and acquired on a FACSCalibur (BD) and 
analyzed using FlowJo software (Tree Star, Inc.).
Confocal microscopy imaging. Cells (5 × 104 cells) were cultured onto poly-l-lysin-coated round cover-
slips for 24 h. Coverslips were then fixed with 4% PFA for 10 min at RT. Cell spots were then blocked with 50 μL 
of PBS (incl. 2% FBS and 2 mM EDTA) for 10 min before adding anti-human CD33-FITC (1/200, eBioscience, 
HIM3-4) and anti-human TLR2-PE (1/50, BioLegend, clone QA16A01) antibodies for 2 h at RT. Cell spots were 
then washed in PBS and analyzed on a Zeiss LSM 700 confocal microcope.
Monocyte‑derived dendritic cells and macrophages. Peripheral blood mononuclear cells were iso-
lated from buffy coats via standard Ficoll centrifugation [Ficoll-Paque PLUS (GE Healthcare)]. To generate 
monocyte-derived dendritic cells (moDCs) or macrophages,  CD14+ cells were isolated from PBMCs using the 
human Monocyte Isolation Kit II (Miltenyi Biotec, Bergisch-Gladbach, Germany). The cells were suspended 
in RPMI 1640 (Gibco) with 10% FCS and penicillin and streptomycin.  CD14+ monocytes (1 × 106  cells/mL) 
were supplemented with 100 ng/mL GM-CSF and 50 ng/mL IL-4 to generate moDCs. For the generation of 
macrophages, 100 ng/mL GM-CSF alone was supplemented. The suspension was incubated for 3 days at 37 °C 
and 5%  CO2. The medium was renewed together with the named cytokines, respectively. At day 6, the cells were 
adjusted to 1 × 106 cells/mL. Macrophages or moDCs cultured in medium only acted as negative controls. Some 
wells were pretreated with either 10 µg/mL anti-hTLR2 or anti-IgA2-control antibody for 45 min prior to the 
addition of IL-26. The stimulants LPS (100 ng/mL), LL37 (10 µM) and IL-26 (2 µM) were added for 24 h.
Enzyme linked immunoassay. Cytokine levels were identified with TNF-α or IL-6 DuoSet ELISA (R&D 
Systems).
Statistics. All analyses were done using GraphPad Prism Version 5.03 (GraphPad Software, Inc.). The “n” 
in the figure legends always refers to the number of independently performed experiments and can thus be con-
sidered as biological replicates. Mann–Whitney U test was used to analyze the diseases and healthy controls. For 
experiments involving cells, the Wilcoxon matched-pairs signed rank test was applied. Statistical significances 
are depicted as follows; * equals P ≤ 0.05, ** equals P ≤ 0.01 and *** equals P ≤ 0.001.
Data availability
No datasets were generated or analyzed during the current study.
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